Alligator Bioscience

Share Issue/Capital Change • Sep 11, 2025

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE.

LAST DAY OF TRADING IN WARRANTS SERIES TO 13 IN ALLIGATOR BIOSCIENCE IS 11 SEPTEMBER 2025

11 September 2025 is the last day of trading in warrants series TO 13 in Alligator Bioscience AB ("Alligator Bioscience " or the "Company"). Subscription of ordinary shares by exercise of warrants series TO 13 is ongoing until 15 September 2025. One thousand (1,000) warrants series TO 13 entitle the holder to subscribe for one (1) new ordinary share in the Company at a subscription price of SEK 3.12 per ordinary share.

Alligator Bioscience carried out a rights issue of units during December 2024 – February 2025 (the "Rights Issue"). Each unit issued in the Rights Issue consisted of ten (10) ordinary shares, ten (10) warrants series TO 12 and five (5) warrants series TO 13. The total number of outstanding warrants series TO 13 amounts to 9,822,884,630. If all warrants series TO 13 are exercised, Alligator Bioscience will receive approximately SEK 30.6 million before issue costs. 11 September 2025 is the last day of trading in warrants series TO 13. Subscription of ordinary shares by exercise of warrants series TO 13 is ongoing until 15 September 2025.

Complete terms and conditions for the warrants are available on the Company's website, www.alligatorbioscience.com.

Summarized terms for warrants series TO 13:

• Structure: One thousand (1,000) warrant series TO 13 entitle the holder to subscribe for one (1) new ordinary share in the Company.
• Exercise period: 1 September 2025 15 September 2025.
• Subscription price: SEK 3.12 per ordinary share.
• Issue volume: 9,822,884,630 warrants series TO 13. Upon full exercise, 9,822,884 ordinary shares will be issued, and the Company will receive approximately SEK 30.6 million before issue costs.
• Last day for trading in warrants series TO 13: 11 September 2025.

• Share capital and dilution: Upon full exercise of all 9,822,884,630 warrants series TO 13, the share capital will increase by a maximum of SEK 7,858,307.20 to SEK 35,701,425.60 through the issuance of a maximum of 9,822,884 new ordinary shares, resulting in that the total number of outstanding shares in the Company will increase from 34,803,898 to 44,626,782, whereof all outstanding shares are ordinary shares. Upon full exercise of all warrants series TO 13, the dilution of the ordinary shares amounts to approximately 22 percent.
• Outcome and delivery of new ordinary shares: The outcome of the exercise of warrants will be published via a press release on or around 17 September 2025. The warrants will be replaced by ordinary shares after the exercise has been registered with the Swedish Companies Registration Office.

Please note that the warrants series TO 13 that are not exercised by 15 September 2025, or sold by 11 September 2025, will expire without value. In order for the warrants not to lose their value, active subscription of ordinary shares or sale of warrants is required. Please note that some nominees may close their application earlier than 15 September 2025.

Advisers

Vator Securities AB acts as Sole Global Coordinator and bookrunner in connection with the Rights Issue and Van Lanschot Kempen N.V. acts as financial adviser to Alligator Bioscience in connection with the Rights Issue. Setterwalls Advokatbyrå AB is legal adviser to Alligator Bioscience in connection with the Rights Issue. Vator Securities AB acts as the issuing agent in connection with the Rights Issue.

For further information, please contact:

Søren Bregenholt, CEO E-mail: soren.bregenholt@alligatorbioscience.com Phone: +46 (0) 46 540 82 00

The information was submitted for publication, through the agency of the contact person set out above, at 8:30 a.m. CEST on 11 September 2025.

About Alligator Bioscience

Alligator is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs focused on the CD40 receptor. This validated approach promotes priming of tumor-specific T cells and reversing the immunosuppressive nature of the tumor microenvironment, with significant potential benefits for cancer patients across multiple types of cancer. The Company's lead drug candidate mitazalimab is currently ready for Phase 3 development, and has previously presented unprecedented survival data at 24-months follow up in first-line metastatic pancreatic cancer patients in the Phase 2 trial OPTIMIZE-1.

Alligator is listed on Nasdaq Stockholm (ATORX) and headquartered in Lund, Sweden.

For more information, please visit alligatorbioscience.com.

IMPORTANT INFORMATION

The information in this press release does not contain or constitute an offer to acquire, subscribe for or otherwise trade in shares, warrants or other securities in Alligator Bioscience. The invitation to the persons concerned to subscribe for units consisting of ordinary shares, warrants series TO 12 and warrants series TO 13 in Alligator Bioscience has only been made through the prospectus published by Alligator Bioscience on 24 January 2025. The prospectus has been approved and registered by the Swedish Financial Supervisory Authority and has been published on the Company's website, www.alligatorbioscience.com.

Since Alligator Bioscience is considered to conduct protection-worthy activities according to the Swedish Screening of Foreign Direct Investments Act (Sw. lag ( 2023:560) om granskning av utländska direktinvesteringar), the exercise of warrants for subscription of ordinary shares may require review by the Inspectorate of Strategic Products (ISP). More information about this can be found on the Company's website, www.alligatorbioscience.com.

Attachments

Last day of trading in warrants series TO 13 in Alligator Bioscience is 11 September 2025